TY - JOUR T1 - Genotype–phenotype correlations and novel molecular insights into the <em>DHX30</em>-associated neurodevelopmental disorders JF - medRxiv DO - 10.1101/2020.09.24.20196097 SP - 2020.09.24.20196097 AU - Ilaria Mannucci AU - Nghi D. P. Dang AU - Hannes Huber AU - Jaclyn B. Murry AU - Jeff Abramson AU - Thorsten Althoff AU - Siddharth Banka AU - Gareth Baynam AU - David Bearden AU - Ana Beleza AU - Paul J. Benke AU - Siren Berland AU - Tatjana Bierhals AU - Frederic Bilan AU - Laurence A. Bindoff AU - Geir Julius Braathen AU - Øyvind L. Busk AU - Jirat Chenbhanich AU - Jonas Denecke AU - Luis F. Escobar AU - Caroline Estes AU - Julie Fleischer AU - Daniel Groepper AU - Charlotte A. Haaxma AU - Maja Hempel AU - Yolanda Holler-Managan AU - Gunnar Houge AU - Adam Jackson AU - Laura Kellogg AU - Boris Keren AU - Catherine Kiraly-Borri AU - Cornelia Kraus AU - Christian Kubisch AU - Gwenael Le Guyader AU - Ulf W. Ljungblad AU - Leslie Manace Brenman AU - Julian A. Martinez-Agosto AU - Matthew Might AU - David T. Miller AU - Kelly Q. Minks AU - Billur Moghaddam AU - Caroline Nava AU - Stanley F. Nelson AU - John M. Parant AU - Trine Prescott AU - Farrah Rajabi AU - Hanitra Randrianaivo AU - Simone F. Reiter AU - Janneke Schuurs-Hoeijmakers AU - Perry B. Shieh AU - Anne Slavotinek AU - Sarah Smithson AU - Alexander P.A Stegmann AU - Kinga Tomczak AU - Kristian Tveten AU - Jun Wang AU - Jordan H. Whitlock AU - Christiane Zweier AU - Kirsty McWalter AU - Jane Juusola AU - Fabiola Quintero-Rivera AU - Utz Fischer AU - Nan Cher Yeo AU - Hans-Jürgen Kreienkamp AU - Davor Lessel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/22/2020.09.24.20196097.abstract N2 - Background We aimed to define the clinical and mutational spectrum, and to provide novel molecular insights into DHX30-associated neurodevelopmental disorder.Methods Clinical and genetic data from affected individuals were collected through family support group, GeneMatcher and our network of collaborators. We investigated the impact of novel missense variants with respect to ATPase and helicase activity, stress granule (SG) formation, global translation, and their effect on embryonic development in zebrafish. SG formation was additionally analyzed in CRISPR/Cas9-mediated DHX30-deficient HEK293T and zebrafish models, along with in vivo behavioral assays.Results We identified 25 previously unreported individuals, ten of whom carry novel variants, two of which are recurrent, and provide evidence of gonadal mosaicism in one family. All 19 individuals harboring heterozygous missense variants within helicase core motifs (HCMs) have global developmental delay, intellectual disability, severe speech impairment and gait abnormalities. These variants impair the ATPase and helicase activity of DHX30, trigger SG formation, interfere with global translation, and cause developmental defects in a zebrafish model. Notably, 4 individuals harboring heterozygous variants resulting either in haploinsufficiency or truncated proteins presented with a milder clinical course, similar to an individual bearing a de novo mosaic HCM missense variant. Functionally, we established DHX30 as an ATP-dependent RNA helicase and as an evolutionary conserved factor in SG assembly. Based on the clinical course, the variant location and type we establish two distinct clinical subtypes. DHX30 loss-of-function mutations cause a milder phenotype whereas a severe phenotype is caused by HCM missense mutations that, in addition to the loss of ATPase and helicase activity, lead to a detrimental gain-of function with respect to SG formation. Behavioral characterization of dhx30 deficient zebrafish revealed altered sleep-wake activity and social interaction, partially resembling the human phenotype.Conclusions Our study highlights the usefulness of social media in order to define novel Mendelian disorders, and exemplifies how functional analyses accompanied by clinical and genetic findings can define clinically distinct subtypes for ultra-rare disorders. Such approaches require close interdisciplinary collaboration between families/legal representatives of the affected individuals, clinicians, molecular genetics diagnostic laboratories and research laboratories.Competing Interest StatementK.M. and J.J. are employees of GeneDx, Inc.Funding StatementThis work was funded in part by Werner Otto Stiftung (to D.L and H-J.K) and Deutsche Forschungsgemeinschaft (LE4223/1-1 to D.L.; Kr1321/8-2 to H-J.K), by the UCLA Pathology Translational Research Fund (to J.B.M. and F.Q-R.) and by the UCLA California Center for Rare Diseases (to S.F.N).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with protocols approved by the respective ethics committees of the institutions involved in this study (approval number by the Ethics Committee of the Hamburg Chamber of Physicians: PV 3802 and the UCLA IRB: 11-001087).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw whole-exome sequencing data that support the findings in affected individual cannot be made publicly available for reasons of patient confidentiality. Qualified researchers may apply for access to these data, pending institutional review board approval. ER -